Article
EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study.
Clinical lung cancer - 1 May 2021
Chang Qing, Xu Jianlin, Qiang Huiping, Teng Jiajun, Qian Jialin, Lv Minfang, Zhang Yanwei, Lou Yuqing, Zhao Yizhuo, Zhong Runbo, Han Baohui, Chu Tianqing
Abstract excerpt
INTRODUCTION: Continuing tyrosine kinase inhibitor (TKI) therapy may be beneficial when patients with non-small-cell lung cancer and EGFR mutations experience gradual disease progression after initial EGFR-TKI treatment. We aimed to compare the efficacy of simultaneous EGFR-TKI and chemotherapy with that of sequential treatment after patients' disease gradually progressed after first-line EGFR-TKI treatment....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.